Table 5.
Basic characteristics of study collective.
| mean | SD | median | range | |
|---|---|---|---|---|
| Age (years) | 72.1 | 7.5 | 73 | 51–89 |
| Days 68GA-PSMA-PET to MRI | 72.7 | 48.4 | 63 | 0–180 |
| Days PSA to 68GA-PSMA-PET | 26.5 | 43 | 0 | 0–193 |
| PSA (ng/ml) | 15.8 | 23.6 | 9.7 | 0.2–196 |
| T-Stage | 2.5 | 0.7 | 2.5 | 1–4 |
| Prostate volume (ml) | 68.8 | 36.0 | 68 | 10–188 |
| Gleason score biopsy | 7, 9 | 1.0 | 8 | 6–10 |
| Gleason score after surgery | 7.7 | 0.9 | 7 | 7–9 |
The basic characteristics of the prostate cancer patients who received a 68Gallium-Prostate specific membrane antigen (68Ga-PSMA) PET-CT and a multiparametric MRI within 180 days investigated in this study are presented in this table. This included the age of the patients, the delay between both imaging modalities, the prostate specific antigen blood level, the delay towards the 68Ga-PSMA PET-CT, prostate volumes, the Gleason scores from biopsy and after surgery and the tumor stages. Data are given in means, standard deviations, medians and ranges.
Abbreviations: PSMA = Prostate specific membrane antigen, PET = Positron emission tomography, MRI = Magnetic resonance imaging, PSA = Prostate specific antigen blood level.